By submitting this form, you are agreeing to the Terms of Use and Privacy Policy.
The chemiluminescence immunoassay system employs magnetic particle separation technology, which employs magnetic particles as antibody carriers and allows for even distribution of the carriers in the liquid phase reaction system, resulting in a faster and more effective reaction time.
The light signal is more stable when using the enzymatic chemiluminescence approach. a more sensitive and luminescently quick production of enzymatic substrates. The chemiluminescence immunoassay reagents offer good consistency when compared to worldwide brands.
Rapid advancements in diagnostic technology have been made in the previous ten years, including the detection of antibodies, bringing this field of diagnosis closer to automated clinical chemistry laboratories.
In this study, we discuss the advantages of chemiluminescence technology for a more rapid and precise diagnosis of autoimmune illnesses as well as its analytical and diagnostic features.
The high sensitivity and specificity of the results expressed in quantitative form, the high degree of automation and the clinical implications related to the reduction in turnaround time, and the ability to run a large number of antibody tests, directed towards large antigenic panels in random access mode, make this approach superior to immunoenzymatic methods in terms of dynamic range.
The Global Automatic Chemiluminescence Immunoassay Analyzer market accounted for $XX Billion in 2023 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.
In the chemiluminescent immunoassay (CLIA) method, a luminescent molecule serves as the label—the actual “indicator” of the analytic response. Generally speaking, luminescence refers to the generation of visible or near-visible radiation during an electron’s transition from an excited to a ground state.
Light is produced as a result of the potential energy release in the atom. Luminescence has an advantage over absorbance in spectrophotometry since the former is an absolute metric while the latter is a relative one.
The identification of autoantibodies is essential for the diagnosis of many autoimmune diseases, including organ-specific conditions like coeliac disease, autoimmune thyroid diseases, primary biliary cirrhosis, and autoimmune hepatitis as well as systemic ones like systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), Sjögren’s syndrome, systemic sclerosis, and antiphospholipid syndrome.
Given that autoantibodies can emerge years before clinical disease manifestation, autoantibody determination is specifically included among categorization and/or diagnostic criteria for some autoimmune disorders and assumes a relevant predictive value in others.
Autoantibody detection has been approached using a variety of analytical techniques. One of them, immunoassay, has recently undergone significant and dramatic changes as a result of ongoing technological advancements that have been sparked by a rise in demand for services similar to those that are already present in other areas of contemporary laboratory diagnostics.
Fundamentally, the advancement of immunoassay labelling technology parallels immunoassay development. The first immunoassay to be created, known as radioimmunoassay (RIA), can be regarded as the ancestor of all subsequent immunoassays.
Abbott Diagnostics created the very sophisticated automated immunoassay analyzer known as the ARCHITECT i2000SR. It is made to offer testing that is both accurate and effective for a variety of immunoassays.
The ARCHITECT i2000SR has established itself as a reliable instrument in clinical laboratories all around the world because to its cutting-edge technology and cutting-edge features.
The automated immunoassay system of the ARCHITECT i2000SR is its brain. This phrase describes the analyzer’s capacity to run immunoassays without the requirement for operator intervention.
The presence or amount of particular compounds in the blood or other physiological fluids can be determined using immunoassays, which are laboratory examinations. They are frequently employed in clinical diagnostics to identify and keep track of a wide range of illnesses, such as infectious infections, autoimmune conditions, and hormone abnormalities.
The ARCHITECT i2000SR’s automated immunoassay technology streamlines the testing procedure, saving time and lowering the possibility of errors.
The analyzer can handle many samples at once because to its sophisticated robotics, pipetting systems, and sample tracking capabilities. With such a high throughput capacity, laboratories are able to efficiently handle a large number of tests, which makes them very useful in environments with a lot of work to do.
The adaptability of the automated immunoassay system for the ARCHITECT i2000SR is one of its main benefits. A comprehensive range of immunoassays, including those for hormones, tumor markers, infectious disease markers, and cardiac biomarkers, are available on the analyzer.
With this extensive test menu, laboratories can accommodate all of their patients’ different testing requirements. The ARCHITECT i2000SR also enables batch processing and random access, giving sample management flexibility.
The ARCHITECT i2000SR automated immunoassay system stands out for its outstanding sensitivity and specificity. Chemiluminescent microparticle immunoassay (CMIA), a technology used by the analyzer, combines the principles of chemiluminescence and immunoassay. Even at low analyte concentrations, our technique guarantees accurate and dependable findings.
The accuracy of the test results is improved by the two-step sandwich immunoassay format used by the ARCHITECT i2000SR. The automated immunoassay system for the ARCHITECT i2000SR has a number of features that improve productivity and workflow in the lab. The system has automated sample preparation, therefore handling samples manually is no longer necessary.
Additionally, it uses intelligent sample routing to reduce waste and maximize reagent consumption. The analyzer also offers a user-friendly interface and intuitive software, making it simple for laboratory staff to explore and utilize the device.
An essential component of immunoassay testing is quality control, and the ARCHITECT i2000SR automated immunoassay system has strong quality control features.
The analyzer includes materials and procedures for quality control, ensuring the dependability and correctness of the test results. Additionally, it provides extensive data management features, enabling labs to keep tabs on and trace the evolution of quality control performance.
Ortho Clinical Diagnostics created the sophisticated automated immunoassay analyzer known as the VITROS ECiQ. With its remarkable accuracy, effectiveness, and usability, this state-of-the-art device is intended to revolutionize the field of immunoassay testing.
The automated immunoassay technology at the heart of the VITROS ECiQ enables high-throughput processing of immunoassay tests with little operator involvement.
This tool uses a special mix of cutting-edge features and sophisticated algorithms to quickly and accurately give results. The VITROS ECiQ’s remarkable analytical performance is one of its main features. A strong chemiluminescent detection system used by the analyzer delivers highly accurate and precise immunoassay measurements.
